FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 328:1002-1006 April 8, 1993 Number 14 Next

	Full Text Letters Letters Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background CHOP is a first-generation, combination-chemotherapy regimen consisting of cyclophosphamide, doxorubicin, vincristine, and prednisone that has cured approximately 30 percent of patients with advanced stages of intermediate-grade or high-grade non-Hodgkin's lymphoma in national cooperative-group trials. However, studies at single institutions have suggested that 55 to 65 percent of such patients might be cured by third-generation regimens such as ones consisting of low-dose methotrexate with leucovorin rescue, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone (m-BACOD); prednisone, doxorubicin, cyclophosphamide, and etoposide, followed by cytarabine, bleomycin, vincristine, and methotrexate with leucovorin rescue (ProMACE-CytaBOM); and methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin (MACOP-B).

Methods To make a valid comparison of these regimens, the Southwest Oncology Group and the Eastern Cooperative Oncology Group initiated a prospective, randomized phase III trial. The study end points were the response rate, time to treatment failure, overall survival, and incidence of severe or life-threatening toxicity. Dose intensity was calculated and analyzed.

Results Of the 1138 patients registered for the trial, 899 were eligible. Each treatment group contained at least 218 patients. Known prognostic factors were equally distributed among the groups. There were no significant differences among the groups in the rates of partial and complete response. At three years, 44 percent of all patients were alive without disease; there were no significant differences between the groups (41 percent in the CHOP and MACOP-B groups and 46 percent in the m-BACOD and ProMACE-CytaBOM groups; P = 0.35). Overall survival at three years was 52 percent (50 percent in the ProMACE-CytaBOM and MACOP-B groups, 52 percent in the m-BACOD group, and 54 percent in the CHOP group; P = 0.90). There was no subgroup of patients in which survival was improved by a third-generation regimen. Fatal toxic reactions occurred in 1 percent of the CHOP group, 3 percent of the ProMACE-CytaBOM group, 5 percent of the m-BACOD group, and 6 percent of the MACOP-B group (P = 0.09).

Conclusions CHOP remains the best available treatment for patients with advanced-stage intermediate-grade or high-grade non-Hodgkin's lymphoma.

Source Information

From the Stritch School of Medicine, Loyola University, Maywood, Ill. (R.I.F., E.R.G.); Southwest Oncology Group Statistical Center, Seattle (S.D., E.M.M.); Virginia Piper Cancer Institute, Abbott Northwestern Hospital, Minneapolis (M.M.O.); the University of Arizona, Tucson (T.M.G., T.P.M.); the University of Pennsylvania, Philadelphia (J.H.G.); and the University of Texas Health Science Center, San Antonio (C.A.C.).

Address reprint requests to the Southwest Oncology Group (SWOG-8516), Operations Office, 5430 Fredericksburg Rd., Suite No. 618, San Antonio, TX 78229-6197.

Full Text of this Article

Related Letters:

CHOP versus Intensive Regimens in Non-Hodgkin's Lymphoma
Longo D. L., DeVita V. T., Young R. C., Salloum E., Levin M., Fisher R. I.
Extract | Full Text  
N Engl J Med 1993; 329:580-582, Aug 19, 1993. Correspondence

Chemotherapy for AIDS-Related Lymphomas
Wilson W. H., Sparano J., Kaplan L. D., Straus D. J., Testa M. A.
Extract | Full Text  
N Engl J Med 1997; 337:1172-1174, Oct 16, 1997. Correspondence

Observational Studies and Randomized Trials
Kunz R., Khan K. S., Neumayer H.-H., Sacks H. S., Liu P.-Y., Anderson G., Crowley J. J., Friedman H. S., Smith R. P., Meier P., Benson K., Hartz A. J., Concato J., Shah N., Horwitz R. I.
Extract | Full Text  
N Engl J Med 2000; 343:1194-1197, Oct 19, 2000. Correspondence

This article has been cited by other articles:

• Gundrum, J. D., Mathiason, M. A., Moore, D. B., Go, R. S. (2009). Primary Testicular Diffuse Large B-Cell Lymphoma: A Population-Based Study on the Incidence, Natural History, and Survival Comparison With Primary Nodal Counterpart Before and After the Introduction of Rituximab. JCO 27: 5227-5232 [Abstract] [Full Text]  
• Derenzini, E., Fina, M. P., Stefoni, V., Pellegrini, C., Venturini, F., Broccoli, A., Gandolfi, L., Pileri, S., Fanti, S., Lopci, E., Castellucci, P., Agostinelli, C., Baccarani, M., Zinzani, P. L. (2009). MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients. Ann Oncol 0: mdp455v1-mdp455 [Abstract] [Full Text]  
• Azim, H.A., Santoro, L., Bociek, R.G., Gandini, S., Malek, R.A., Azim, H.A. Jr (2009). High dose intensity doxorubicin in aggressive non-Hodgkin's lymphoma: a literature-based meta-analysis. Ann Oncol 0: mdp425v1-mdp425 [Abstract] [Full Text]  
• Brusamolino, E. (2009). First-line therapy of CD20+ diffuse large B-cell lymphoma: facts and open questions. haematol 94: 1194-1198 [Full Text]  
• Vitolo, U., Chiappella, A., Angelucci, E., Rossi, G., Liberati, A. M., Cabras, M. G., Botto, B., Ciccone, G., Gaidano, G., Falchi, L., Freilone, R., Novero, D., Orsucci, L., Pavone, V., Pogliani, E., Rota-Scalabrini, D., Salvi, F., Tonso, A., Tucci, A., Levis, A., on behalf of Gruppo Italiano Multiregionale Linfom, (2009). Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study. haematol 94: 1250-1258 [Abstract] [Full Text]  
• RUSCITTI, C., GUADAGNI, S., RUSSO, F., PALUMBO, G., FIORENTINI, G., MAMBRINI, A., CANTORE, M., KANAVOS, E., PINTO, A., AMICUCCI, G. (2009). Thoracic Stop-flow Perfusion for Refractory Lymphoma: A Phase I-II Evaluation Trial. In Vivo 23: 447-457 [Abstract] [Full Text]  
• MANOLOPOULOS, L., GOMATOS, I. P, LEANDROS, E., ALEVIZOS, L., GEORGIOU, N., GIOTAKIS, J., FEREKIDIS, E. (2009). Use of Rituximab in Combination with Conventional Chemotherapy for the Treatment of Non-Hodgkin's Lymphoma of the Head and Neck. In Vivo 23: 475-478 [Abstract] [Full Text]  
• NISHIMORI, H., FUJII, N., MAEDA, Y., MATSUOKA, K.-I., TAKENAKA, K., SHINAGAWA, K., IKEDA, K., MATSUO, K., HARADA, M., TANIMOTO, M. (2009). Efficacy and Feasibility of IDEA Therapy for Refractory or Relapsed Non-Hodgkin's Lymphoma. Anticancer Res 29: 1749-1754 [Abstract] [Full Text]  
• Ennishi, D., Yokoyama, M., Terui, Y., Asai, H., Sakajiri, S., Mishima, Y., Takahashi, S., Komatsu, H., Ikeda, K., Takeuchi, K., Tanimoto, M., Hatake, K. (2009). Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy. Ann Oncol 20: 526-533 [Abstract] [Full Text]  
• Bernstein, S. H., Unger, J. M., LeBlanc, M., Friedberg, J., Miller, T. P., Fisher, R. I. (2009). Natural History of CNS Relapse in Patients With Aggressive Non-Hodgkin's Lymphoma: A 20-Year Follow-Up Analysis of SWOG 8516--The Southwest Oncology Group. JCO 27: 114-119 [Abstract] [Full Text]  
• Lenz, G., Wright, G., Dave, S.S., Xiao, W., Powell, J., Zhao, H., Xu, W., Tan, B., Goldschmidt, N., Iqbal, J., Vose, J., Bast, M., Fu, K., Weisenburger, D.D., Greiner, T.C., Armitage, J.O., Kyle, A., May, L., Gascoyne, R.D., Connors, J.M., Troen, G., Holte, H., Kvaloy, S., Dierickx, D., Verhoef, G., Delabie, J., Smeland, E.B., Jares, P., Martinez, A., Lopez-Guillermo, A., Montserrat, E., Campo, E., Braziel, R.M., Miller, T.P., Rimsza, L.M., Cook, J.R., Pohlman, B., Sweetenham, J., Tubbs, R.R., Fisher, R.I., Hartmann, E., Rosenwald, A., Ott, G., Muller-Hermelink, H.-K., Wrench, D., Lister, T.A., Jaffe, E.S., Wilson, W.H., Chan, W.C., Staudt, L.M., the Lymphoma/Leukemia Molecular Profiling Project, (2008). Stromal Gene Signatures in Large-B-Cell Lymphomas. NEJM 359: 2313-2323 [Abstract] [Full Text]  
• Ennishi, D., Takeuchi, K., Yokoyama, M., Asai, H., Mishima, Y., Terui, Y., Takahashi, S., Komatsu, H., Ikeda, K., Yamaguchi, M., Suzuki, R., Tanimoto, M., Hatake, K. (2008). CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol 19: 1921-1926 [Abstract] [Full Text]  
• Bishop, M. R., Dean, R. M., Steinberg, S. M., Odom, J., Pavletic, S. Z., Chow, C., Pittaluga, S., Sportes, C., Hardy, N. M., Gea-Banacloche, J., Kolstad, A., Gress, R. E., Fowler, D. H. (2008). Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation. Ann Oncol 19: 1935-1940 [Abstract] [Full Text]  
• Taichman, D. B. (2008). Therapy for Pulmonary Arterial Hypertension: The More, the Merrier?. ANN INTERN MED 149: 583-585 [Full Text]  
• Cheson, B. D., Leonard, J. P. (2008). Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma. NEJM 359: 613-626 [Full Text]  
• Martin, P., Chadburn, A., Christos, P., Furman, R., Ruan, J., Joyce, M. A., Fusco, E., Glynn, P., Elstrom, R., Niesvizky, R., Feldman, E. J., Shore, T. B., Schuster, M. W., Ely, S., Knowles, D. M., Chen-Kiang, S., Coleman, M., Leonard, J. P. (2008). Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. Ann Oncol 19: 1327-1330 [Abstract] [Full Text]  
• Wilson, W. H., Dunleavy, K., Pittaluga, S., Hegde, U., Grant, N., Steinberg, S. M., Raffeld, M., Gutierrez, M., Chabner, B. A., Staudt, L., Jaffe, E. S., Janik, J. E. (2008). Phase II Study of Dose-Adjusted EPOCH and Rituximab in Untreated Diffuse Large B-Cell Lymphoma With Analysis of Germinal Center and Post-Germinal Center Biomarkers. JCO 26: 2717-2724 [Abstract] [Full Text]  
• Hosing, C., Saliba, R. M., Okoroji, G.-J., Popat, U., Couriel, D., Ali, T., De Padua Silva, L., Kebriaei, P., Alousi, A., De Lima, M., Qazilbash, M., Anderlini, P., Giralt, S., Champlin, R. E., Khouri, I. (2008). High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of age. Ann Oncol 19: 1166-1171 [Abstract] [Full Text]  
• Canellos, G. P. (2008). What Constitutes "Improved Prognosis"?. JCO 26: 1913-1914 [Full Text]  
• Zinzani, P. L., Tani, M., Fanti, S., Stefoni, V., Musuraca, G., Castellucci, P., Marchi, E., Farsad, M., Fina, M., Pellegrini, C., Alinari, L., Derenzini, E., de Vivo, A., Bacci, F., Pileri, S., Baccarani, M. (2008). A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. Ann Oncol 19: 769-773 [Abstract] [Full Text]  
• Ulaner, G. A., Colletti, P. M., Conti, P. S. (2008). B-Cell Non-Hodgkin Lymphoma: PET/CT Evaluation after 90Y-Ibritumomab Tiuxetan Radioimmunotherapy--Initial Experience. Radiology 246: 895-902 [Abstract] [Full Text]  
• Aboud, A., Marx, G., Sayer, H., Gummert, J. F. (2008). Successful treatment of an aggressive non-Hodgkin's lymphoma associated with acute respiratory insufficiency using extracorporeal membrane oxygenation. ICVTS 7: 173-174 [Abstract] [Full Text]  
• Sasaki, S., Shikama, N., Koiwai, K., Kadoya, M. (2008). Relationship Between the Response to Treatment and the Prognosis of Patients with Aggressive Lymphomas Treated with Chemotherapy Followed by Involved-field Radiotherapy: Radiographic Assessment. Jpn J Clin Oncol 38: 43-48 [Abstract] [Full Text]  
• Savage, K. J. (2008). Prognosis and Primary Therapy in Peripheral T-Cell Lymphomas. ASH Education Book 2008: 280-288 [Abstract] [Full Text]  
• Horwitz, S. M. (2008). Novel Therapies and Role of Transplant in the Treatment of Peripheral T-Cell Lymphomas. ASH Education Book 2008: 289-296 [Abstract] [Full Text]  
• Johnson, P. W.M., Davies, A. J. (2008). Primary Mediastinal B-Cell Lymphoma. ASH Education Book 2008: 349-358 [Abstract] [Full Text]  
• Moskowitz, C. H., Hamlin, P. A., Gabrilove, J., Bertino, J. R., Portlock, C. S., Straus, D. J., Gencarelli, A. N., Nimer, S. D., Zelenetz, A. D. (2007). Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma. Ann Oncol 18: 1842-1850 [Abstract] [Full Text]  
• Gallamini, A., Zaja, F., Patti, C., Billio, A., Specchia, M. R., Tucci, A., Levis, A., Manna, A., Secondo, V., Rigacci, L., Pinto, A., Iannitto, E., Zoli, V., Torchio, P., Pileri, S., Tarella, C. (2007). Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 110: 2316-2323 [Abstract] [Full Text]  
• Kogan, N. M., Schlesinger, M., Peters, M., Marincheva, G., Beeri, R., Mechoulam, R. (2007). A Cannabinoid Anticancer Quinone, HU-331, Is More Potent and Less Cardiotoxic Than Doxorubicin: A Comparative in Vivo Study. J. Pharmacol. Exp. Ther. 322: 646-653 [Abstract] [Full Text]  
• DeNardo, G. L., Natarajan, A., Hok, S., Perkins, J., Cosman, M., DeNardo, S. J., Lightstone, F. C., Mirick, G. R., Miers, L. A., Balhorn, R. L. (2007). Pharmacokinetic Characterization in Xenografted Mice of a Series of First-Generation Mimics for HLA-DR Antibody, Lym-1, as Carrier Molecules to Image and Treat Lymphoma. JNM 48: 1338-1347 [Abstract] [Full Text]  
• Armitage, J. O. (2007). How I treat patients with diffuse large B-cell lymphoma. Blood 110: 29-36 [Full Text]  
• Morschhauser, F., Illidge, T., Huglo, D., Martinelli, G., Paganelli, G., Zinzani, P. L., Rule, S., Liberati, A. M., Milpied, N., Hess, G., Stein, H., Kalmus, J., Marcus, R. (2007). Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood 110: 54-58 [Abstract] [Full Text]  
• Thieblemont, C., Coiffier, B. (2007). Lymphoma in Older Patients. JCO 25: 1916-1923 [Abstract] [Full Text]  
• Schulz, H., Bohlius, J. F., Trelle, S., Skoetz, N., Reiser, M., Kober, T., Schwarzer, G., Herold, M., Dreyling, M., Hallek, M., Engert, A. (2007). Immunochemotherapy With Rituximab and Overall Survival in Patients With Indolent or Mantle Cell Lymphoma: A Systematic Review and Meta-analysis. JNCI J Natl Cancer Inst 99: 706-714 [Abstract] [Full Text]  
• Veelken, H, Vik Dannheim, S, Schulte Moenting, J, Martens, U., Finke, J, Schmitt-Graeff, A (2007). Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy. Ann Oncol 18: 931-939 [Abstract] [Full Text]  
• Mohammad, R. M., Goustin, A. S., Aboukameel, A., Chen, B., Banerjee, S., Wang, G., Nikolovska-Coleska, Z., Wang, S., Al-Katib, A. (2007). Preclinical Studies of TW-37, a New Nonpeptidic Small-Molecule Inhibitor of Bcl-2, in Diffuse Large Cell Lymphoma Xenograft Model Reveal Drug Action on Both Bcl-2 and Mcl-1. Clin. Cancer Res. 13: 2226-2235 [Abstract] [Full Text]  
• Verdonck, L. F., Notenboom, A., de Jong, D. D., MacKenzie, M. A., Verhoef, G. E. G., Kramer, M. H. H., Ossenkoppele, G. J., Doorduijn, J. K., Sonneveld, P., van Imhoff, G. W. (2007). Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). Blood 109: 2759-2766 [Abstract] [Full Text]  
• Sehn, L. H., Berry, B., Chhanabhai, M., Fitzgerald, C., Gill, K., Hoskins, P., Klasa, R., Savage, K. J., Shenkier, T., Sutherland, J., Gascoyne, R. D., Connors, J. M. (2007). The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109: 1857-1861 [Abstract] [Full Text]  
• Boehme, V, Zeynalova, S, Kloess, M, Loeffler, M, Kaiser, U, Pfreundschuh, M, Schmitz, N (2007). Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 18: 149-157 [Abstract] [Full Text]  
• Habermann, T. M. (2007). Antibody Therapy in Aggressive Lymphomas. ASH Education Book 2007: 257-264 [Abstract] [Full Text]  
• Sandlund, J. T. (2007). Should Adolescents with NHL Be Treated as Old Children or Young Adults?. ASH Education Book 2007: 297-303 [Abstract] [Full Text]  
• Venugopal, P., Gregory, S. A. (2007). Lymphoproliferative disorders. ASH-SAP 2007: 265-297 [Full Text]  
• Betticher, D., Martinelli, G, Radford, J., Kaufmann, M, Dyer, M., Kaiser, U, Aulitzky, W., Beck, J, von Rohr, A, Kovascovics, T, Cogliatti, S., Cina, S, Maibach, R, Cerny, T, Linch, D. (2006). Sequential high dose chemotherapy as initial treatment for aggressive sub-types of Non-Hodgkin Lymphoma: results of the international randomized phase III trial (MISTRAL). Ann Oncol 17: 1546-1552 [Abstract] [Full Text]  
• Bouzani, M., Karmiris, T., Rontogianni, D., Delimpassi, S., Apostolidis, J., Mpakiri, M., Nikiforakis, E. (2006). Disseminated Intravascular B-Cell Lymphoma: Clinicopathological Features and Outcome of Three Cases Treated with Anthracycline-Based Immunochemotherapy. The Oncologist 11: 923-928 [Abstract] [Full Text]  
• Smith, T. J., Khatcheressian, J., Lyman, G. H., Ozer, H., Armitage, J. O., Balducci, L., Bennett, C. L., Cantor, S. B., Crawford, J., Cross, S. J., Demetri, G., Desch, C. E., Pizzo, P. A., Schiffer, C. A., Schwartzberg, L., Somerfield, M. R., Somlo, G., Wade, J. C., Wade, J. L., Winn, R. J., Wozniak, A. J., Wolff, A. C. (2006). 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline. JCO 24: 3187-3205 [Abstract] [Full Text]  
• Habermann, T. M., Weller, E. A., Morrison, V. A., Gascoyne, R. D., Cassileth, P. A., Cohn, J. B., Dakhil, S. R., Woda, B., Fisher, R. I., Peterson, B. A., Horning, S. J. (2006). Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma. JCO 24: 3121-3127 [Abstract] [Full Text]  
• Jacobsen, E. (2006). Anaplastic Large-Cell Lymphoma, T-/Null-Cell Type. The Oncologist 11: 831-840 [Abstract] [Full Text]  
• Dave, S. S., Fu, K., Wright, G. W., Lam, L. T., Kluin, P., Boerma, E.-J., Greiner, T. C., Weisenburger, D. D., Rosenwald, A., Ott, G., Muller-Hermelink, H.-K., Gascoyne, R. D., Delabie, J., Rimsza, L. M., Braziel, R. M., Grogan, T. M., Campo, E., Jaffe, E. S., Dave, B. J., Sanger, W., Bast, M., Vose, J. M., Armitage, J. O., Connors, J. M., Smeland, E. B., Kvaloy, S., Holte, H., Fisher, R. I., Miller, T. P., Montserrat, E., Wilson, W. H., Bahl, M., Zhao, H., Yang, L., Powell, J., Simon, R., Chan, W. C., Staudt, L. M., the Lymphoma/Leukemia Molecular Profiling Project, (2006). Molecular diagnosis of Burkitt's lymphoma.. NEJM 354: 2431-2442 [Abstract] [Full Text]  
• Ganti, A. K., Weisenburger, D. D., Smith, L. M., Hans, C. P., Bociek, R. G., Bierman, P. J., Vose, J. M., Armitage, J. O. (2006). Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience. Ann Oncol 17: 920-927 [Abstract] [Full Text]  
• Liedtke, M., Hamlin, P. A., Moskowitz, C. H., Zelenetz, A. D. (2006). Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. Ann Oncol 17: 909-913 [Abstract] [Full Text]  
• Cheson, B. D., Canellos, G. P. (2006). The cancer and leukemia group B lymphoma committee.. Clin. Cancer Res. 12: 3572s-3575s [Abstract] [Full Text]  
• Mounier, N., Spina, M., Gabarre, J., Raphael, M., Rizzardini, G., Golfier, J.-B., Vaccher, E., Carbone, A., Coiffier, B., Chichino, G., Bosly, A., Tirelli, U., Gisselbrecht, C., for the French-Italian cooperative group, (2006). AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood 107: 3832-3840 [Abstract] [Full Text]  
• Savage, K. J. (2006). Primary mediastinal large B-cell lymphoma.. The Oncologist 11: 488-495 [Abstract] [Full Text]  
• Glass, B., Kloess, M., Bentz, M., Schlimok, G., Berdel, W. E., Feller, A., Trumper, L., Loeffler, M., Pfreundschuh, M., Schmitz, N., for the German High-Grade Non-Hodgkin Lymphoma Stu, (2006). Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma. Blood 107: 3058-3064 [Abstract] [Full Text]  
• Gobbi, P. G., Broglia, C., Valentino, F., Mammi, C., Lombardo, M., Merli, F., Luminari, S., Polimeno, G., Riezzo, A., Lambelet, P., Rovati, A., Corazza, G. R., Federico, M. (2006). The role of dose size in a chemotherapy regimen (ProMECE-CytaBOM) for the first-line treatment of large B-cell lymphomas: a randomized trial by the Gruppo Italiano Studio Linfomi (GISL). Ann Oncol 17: 676-682 [Abstract] [Full Text]  
• Moser, E. C., Noordijk, E. M., van Leeuwen, F. E., le Cessie, S., Baars, J. W., Thomas, J., Carde, P., Meerwaldt, J. H., van Glabbeke, M., Kluin-Nelemans, H. C. (2006). Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood 107: 2912-2919 [Abstract] [Full Text]  
• Lossos, I. S., Morgensztern, D. (2006). Prognostic Biomarkers in Diffuse Large B-Cell Lymphoma. JCO 24: 995-1007 [Abstract] [Full Text]  
• Rizvi, M. A., Evens, A. M., Tallman, M. S., Nelson, B. P., Rosen, S. T. (2006). T-cell non-Hodgkin lymphoma. Blood 107: 1255-1264 [Abstract] [Full Text]  
• Toner, L. E., Vrhovac, R., Smith, E. A., Gardner, J., Heaney, M., Gonen, M., Teruya-Feldstein, J., Sirotnak, F., O'Connor, O. A. (2006). The Schedule-Dependent Effects of the Novel Antifolate Pralatrexate and Gemcitabine Are Superior to Methotrexate and Cytarabine in Models of Human Non-Hodgkin's Lymphoma. Clin. Cancer Res. 12: 924-932 [Abstract] [Full Text]  
• Savage, K. J., Al-Rajhi, N., Voss, N., Paltiel, C., Klasa, R., Gascoyne, R. D., Connors, J. M. (2006). Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol 17: 123-130 [Abstract] [Full Text]  
• Olivieri, A., Santini, G., Patti, C., Chisesi, T., De Souza, C., Rubagotti, A., Aversa, S., Billio, A., Porcellini, A., Candela, M., Centurioni, R., Congiu, A. M., Brunori, M., Nati, S., Spriano, M., Vimercati, R., Marino, G., Contu, A., Tedeschi, L., Majolino, I., Crugnola, M., Sertoli, M. R. (2005). Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: long-term results by the NHLCSG. Ann Oncol 16: 1941-1948 [Abstract] [Full Text]  
• Sakane-Ishikawa, E., Nakatsuka, S.-i., Tomita, Y., Fujita, S., Nakamichi, I., Takakuwa, T., Sugiyama, H., Fukuhara, S., Hino, M., Kanamaru, A., Soma, T., Tsukaguchi, M., Igarashi, K., Kanakura, Y., Aozasa, K. (2005). Prognostic Significance of BACH2 Expression in Diffuse Large B-Cell Lymphoma: A Study of the Osaka Lymphoma Study Group. JCO 23: 8012-8017 [Abstract] [Full Text]  
• Armitage, J. O. (2005). Staging Non-Hodgkin Lymphoma. CA Cancer J Clin 55: 368-376 [Abstract] [Full Text]  
• Nademanee, A., Forman, S., Molina, A., Fung, H., Smith, D., Dagis, A., Kwok, C., Yamauchi, D., Anderson, A.-L., Falk, P., Krishnan, A., Kirschbaum, M., Kogut, N., Nakamura, R., O'Donnell, M., Parker, P., Popplewell, L., Pullarkat, V., Rodriguez, R., Sahebi, F., Smith, E., Snyder, D., Stein, A., Spielberger, R., Zain, J., White, C., Raubitschek, A. (2005). A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 106: 2896-2902 [Abstract] [Full Text]  
• Wong, E. T. (2005). Management of Central Nervous System Lymphomas Using Monoclonal Antibodies: Challenges and Opportunities. Clin. Cancer Res. 11: 7151s-7157s [Abstract] [Full Text]  
• Coiffier, B. (2005). State-of-the-Art Therapeutics: Diffuse Large B-Cell Lymphoma. JCO 23: 6387-6393 [Abstract] [Full Text]  
• Khoury, H. J., DiPersio, J. F. (2005). In Reply:. JCO 23: 6262-6262 [Full Text]  
• Mikhaeel, N. G., Hutchings, M., Fields, P. A., O'Doherty, M. J., Timothy, A. R. (2005). FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 16: 1514-1523 [Abstract] [Full Text]  
• Wasil, T., Lichtman, S. M. (2005). Clinical Pharmacology Issues Relevant to the Dosing and Toxicity of Chemotherapy Drugs in the Elderly. The Oncologist 10: 602-612 [Abstract] [Full Text]  
• Tagawa, H., Suguro, M., Tsuzuki, S., Matsuo, K., Karnan, S., Ohshima, K., Okamoto, M., Morishima, Y., Nakamura, S., Seto, M. (2005). Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. Blood 106: 1770-1777 [Abstract] [Full Text]  
• Leonard, J. P., Coleman, M., Ketas, J., Ashe, M., Fiore, J. M., Furman, R. R., Niesvizky, R., Shore, T., Chadburn, A., Horne, H., Kovacs, J., Ding, C. L., Wegener, W. A., Horak, I. D., Goldenberg, D. M. (2005). Combination Antibody Therapy With Epratuzumab and Rituximab in Relapsed or Refractory Non-Hodgkin's Lymphoma. JCO 23: 5044-5051 [Abstract] [Full Text]  
• Sehn, L. H., Donaldson, J., Chhanabhai, M., Fitzgerald, C., Gill, K., Klasa, R., MacPherson, N., O'Reilly, S., Spinelli, J. J., Sutherland, J., Wilson, K. S., Gascoyne, R. D., Connors, J. M. (2005). Introduction of Combined CHOP Plus Rituximab Therapy Dramatically Improved Outcome of Diffuse Large B-Cell Lymphoma in British Columbia. JCO 23: 5027-5033 [Abstract] [Full Text]  
• Ansell, S. M., Armitage, J. (2005). Non-Hodgkin Lymphoma: Diagnosis and Treatment. Mayo Clin Proc. 80: 1087-1097 [Abstract]  
• Lin, T. S., Grever, M. R., Byrd, J. C. (2005). Changing the Way We Think About Chronic Lymphocytic Leukemia. JCO 23: 4009-4012 [Full Text]  
• Feugier, P., Van Hoof, A., Sebban, C., Solal-Celigny, P., Bouabdallah, R., Ferme, C., Christian, B., Lepage, E., Tilly, H., Morschhauser, F., Gaulard, P., Salles, G., Bosly, A., Gisselbrecht, C., Reyes, F., Coiffier, B. (2005). Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte. JCO 23: 4117-4126 [Abstract] [Full Text]  
• van Imhoff, G. W., van der Holt, B., MacKenzie, M. A., van't Veer, M. B., Wijermans, P. W., Ossenkoppele, G. J., Schouten, H. C., Sonneveld, P., Steijaert, M. M.C., Kluin, P. M., Kluin-Nelemans, H. C., Verdonck, L. F. (2005). Impact of Three Courses of Intensified CHOP Prior to High-Dose Sequential Therapy Followed by Autologous Stem-Cell Transplantation As First-Line Treatment in Poor-Risk, Aggressive Non-Hodgkin's Lymphoma: Comparative Analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40. JCO 23: 3793-3801 [Abstract] [Full Text]  
• Movsas, B., Scott, C., Langer, C., Werner-Wasik, M., Nicolaou, N., Komaki, R., Machtay, M., Smith, C., Axelrod, R., Sarna, L., Wasserman, T., Byhardt, R. (2005). Randomized Trial of Amifostine in Locally Advanced Non-Small-Cell Lung Cancer Patients Receiving Chemotherapy and Hyperfractionated Radiation: Radiation Therapy Oncology Group Trial 98-01. JCO 23: 2145-2154 [Abstract] [Full Text]  
• Banham, A. H., Connors, J. M., Brown, P. J., Cordell, J. L., Ott, G., Sreenivasan, G., Farinha, P., Horsman, D. E., Gascoyne, R. D. (2005). Expression of the FOXP1 Transcription Factor Is Strongly Associated with Inferior Survival in Patients with Diffuse Large B-Cell Lymphoma. Clin. Cancer Res. 11: 1065-1072 [Abstract] [Full Text]  
• Blayney, D. W., McGuire, B. W., Cruickshank, S. E., Johnson, D. H. (2005). Increasing Chemotherapy Dose Density and Intensity: Phase I Trials in Non-Small Cell Lung Cancer and Non-Hodgkin's Lymphoma. The Oncologist 10: 138-149 [Abstract] [Full Text]  
• Vose, J. M., Bierman, P. J., Enke, C., Hankins, J., Bociek, G., Lynch, J. C., Armitage, J. O. (2005). Phase I Trial of Iodine-131 Tositumomab With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation for Relapsed Non-Hodgkin's Lymphoma. JCO 23: 461-467 [Abstract] [Full Text]  
• Mohammad, R. M., Wang, S., Aboukameel, A., Chen, B., Wu, X., Chen, J., Al-Katib, A. (2005). Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-XL [(-)-gossypol] against diffuse large cell lymphoma. Molecular Cancer Therapeutics 4: 13-21 [Abstract] [Full Text]  
• Savage, K. J. (2005). Aggressive Peripheral T-Cell Lymphomas (Specified and Unspecified Types). ASH Education Book 2005: 267-277 [Abstract] [Full Text]  
• Kazama, T., Faria, S. C., Varavithya, V., Phongkitkarun, S., Ito, H., Macapinlac, H. A. (2005). FDG PET in the Evaluation of Treatment for Lymphoma: Clinical Usefulness and Pitfalls. RadioGraphics 25: 191-207 [Abstract] [Full Text]  
• Mounier, N., Gisselbrecht, C., Briere, J., Haioun, C., Feugier, P., Offner, F., Recher, C., Stamatoullas, A., Morschhauser, F., Macro, M., Thieblemont, C., Sonet, A., Fabiani, B., Reyes, F., On behalf of the Groupe d'Etude des Lymphomes de l, (2004). All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Ann Oncol 15: 1790-1797 [Abstract] [Full Text]  
• Czuczman, M. S., Weaver, R., Alkuzweny, B., Berlfein, J., Grillo-Lopez, A. J. (2004). Prolonged Clinical and Molecular Remission in Patients With Low-Grade or Follicular Non-Hodgkin's Lymphoma Treated With Rituximab Plus CHOP Chemotherapy: 9-Year Follow-Up. JCO 22: 4711-4716 [Abstract] [Full Text]  
• Katahira, T., Takayama, T., Miyanishi, K., Hayashi, T., Ikeda, T., Takahashi, Y., Takimoto, R., Matsunaga, T., Kato, J., Niitsu, Y. (2004). Plasma Glutathione S-Transferase P1-1 as a Prognostic Factor in Patients with Advanced Non-Hodgkin's Lymphoma (Stages III and IV). Clin. Cancer Res. 10: 7934-7940 [Abstract] [Full Text]  
• Lyman, G. H., Dale, D. C., Friedberg, J., Crawford, J., Fisher, R. I. (2004). Incidence and Predictors of Low Chemotherapy Dose-Intensity in Aggressive Non-Hodgkin's Lymphoma: A Nationwide Study. JCO 22: 4302-4311 [Abstract] [Full Text]  
• Portlock, C. S., Qin, J., Schaindlin, P., Roistacher, N., Myers, J., Filippa, D., Louie, D., Zelenetz, A. D., O'Brien, J. P., Moskowitz, C., Norton, L., Yahalom, J., Straus, D. J., Bertino, J. R. (2004). The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide. Ann Oncol 15: 1495-1503 [Abstract] [Full Text]  
• Rodriguez, J., Caballero, M. D., Gutierrez, A., Solano, C., Arranz, R., Lahuerta, J. J., Sierra, J., Gandarillas, M., Perez-Simon, J. A., Zuazu, J., Lopez-Guillermo, A., Sureda, A., Carreras, E., Garcia-Larana, J., Marin, J., Garcia, J. C., Fernandez de Sevilla, A., Rifon, J., Varela, R., Jarque, I., Albo, C., Leon, A., SanMiguel, J., Conde, E. (2004). Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin's lymphoma not achieving complete response after induction chemotherapy: the GEL/TAMO experience. Ann Oncol 15: 1504-1509 [Abstract] [Full Text]  
• Bertz, H., Zeiser, R., Lange, W., Fetscher, S., Waller, C. F., Finke, J. (2004). Long-term follow-up after high-dose chemotherapy and autologous stem-cell transplantation for high-grade B-cell lymphoma suggests an improved outcome for high-risk patients with respect to the age-adjusted International Prognostic Index. Ann Oncol 15: 1419-1424 [Abstract] [Full Text]  
• Friedberg, J. W. (2004). Developing New Monoclonal Antibodies for Aggressive Lymphoma: A Challenging Road in the Rituximab Era. Clin. Cancer Res. 10: 5297-5298 [Full Text]